title: Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis.
authors.affiliation: Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: S
authors.initials: S
authors.lastname: Verstovsek
authors.affiliation: Department of Internal Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
authors.forename: E
authors.initials: E
authors.lastname: Atallah
authors.affiliation: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
authors.forename: J
authors.initials: J
authors.lastname: Mascarenhas
authors.affiliation: Incyte Corporation, Wilmington, DE, USA.
authors.forename: H
authors.initials: H
authors.lastname: Sun
authors.affiliation: Incyte Corporation, Wilmington, DE, USA.
authors.forename: M
authors.initials: M
authors.lastname: Montgomery
authors.affiliation: Department of Medicine, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
authors.forename: V
authors.initials: V
authors.lastname: Gupta
authors.affiliation: Division of Hematology & Medical Oncology, Mayo Clinic Cancer Center, Scottsdale, AZ, USA.
authors.forename: R
authors.initials: R
authors.lastname: Mesa
authors.affiliation: Department of Medicine/Division of Hematology, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA, USA.
authors.forename: J
authors.initials: J
authors.lastname: Gotlib
mesh_terms: D004311:Double-Blind Method; D006529:Hepatomegaly / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D009570:Nitriles; D010919:Placebos; D055728:Primary Myelofibrosis / Q000150:complications*; D011720:Pyrazoles / Q000627:therapeutic use*; D011743:Pyrimidines; D016896:Treatment Outcome
chemical_list: D009570:Nitriles; D010919:Placebos; D011720:Pyrazoles; D011743:Pyrimidines; C540383:ruxolitinib